Erratum to: Islet Xeno/transplantation and the risk of contagion: local responses from Canada and Australia to an emerging global technoscience by unknown
Cheng Life Sciences, Society and Policy  (2016) 12:2 
DOI 10.1186/s40504-016-0035-5ERRATUM Open AccessErratum to: Islet Xeno/transplantation and
the risk of contagion: local responses from




University of Technology Sydney,




cRegretfully, the original version of this article (Cheng 2015) was not fully amended be-
fore publication. For completeness, the author wishes to amend six sections as set out
below. In addition, the Abbreviation and Acknowledgment sections have been updated
via this Erratum.
(i) On page 6 of the original PDF, the following two sentences should be deleted:
PERV transmission and infection has been documented in laboratory animals but not
in human patients. For example, diabetic immuno-compromised mice were infected by
PERV following transplantation of porcine islet cells (Van der Laan et al. 2000).
The above text should be replaced with the following:
PERV transmission in vivo has neither been confirmed in human patients nor la-
boratory animals. Previously, diabetic immuno-compromised mice were shown to be
infected by PERV, without adverse effects, following transplantation of porcine islet
cells (Van der Laan et al. 2000). However, in a subsequent paper, another group of re-
searchers reported that the results of this study could not be reproduced (Irgang et al.
2005). The possibility of in vivo PERV transmission has been debated since it is argued
that xenograft patients are unlikely to be ‘as severely immunosuppressed as SCID mice’
((Björklund et al. 2003), 444).
(ii)On page 15 of the original PDF, the following should be deleted (including endnote 14):
The Australian guidelines for such research do not appear to be available on-line.
On its webpage on xenotransplantation research, the NHMRC stated that it ‘has is-
sued, using advice from its Australian Health Ethics Committee and Animal Welfare
Committee, guidance for researchers and ethics committees involved in animal to hu-
man studies.’ However, the only documents on this webpage are ‘archived publications’
made available for ‘historical purposes only.’ [14].
(iii)On page 17 of the original PDF, the following two sentences should be deleted:2016 Cheng. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided
ou give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
hanges were made.
Cheng Life Sciences, Society and Policy  (2016) 12:2 Page 2 of 3Based on those results, US researchers are now in the process of seeking approval
from the FDA to provide islet transplants as a clinical therapy. It is anticipated that ap-
proval may be forthcoming in the near future.
The above text should be replaced with the following:
Currently, in the US, islet allotransplantation remains an experimental procedure.
(iv)On page 19 of the original PDF, the following two sentences should be deleted:
Though the NHMRC has indicated that it has issued guidelines for ‘animal to human
studies,’ this document do not appear to be available on their website. Within a consen-
sual model of decision-making, Australian efforts to engage in experimental democracy
appear to become un-done when competing national priorities for scientific innovation
took precedence in 2009.
The above text should be replaced with the following:
More than six years since the expiry of the Australian xenotransplantation moratorium,
national regulation and guidelines for clinical xenotransplantation have yet to be finalised
and implemented.
(v)On page 19 of the original PDF, after the final sentence of the third concluding
paragraph, an additional sentence should be added:
In Canada, the role of the public in policy decision-making was underscored following a
medical scandal concerning patients infected by HIV and hepatitis C virus due to the con-
tamination of blood products and local blood supply ((Einsiedel et al. 2011a), 624).
(vi)On pages 19–20 of the original PDF, the final paragraph should be substituted with
the following text:
In summary, this paper compared and contrasted Canadian and Australian responses
to scientific controversies over xenotransplantation in the context of the history of islet
transplantation. My comparative historical narrative illustrates that public conflicts over
islet allograft and xenograft render visible the ambiguity of our taken for granted
boundaries concerning species difference, disciplinary knowledge, and risk management
in transplantation surgery and experimentation. As noted above, the Australian ban on
clinical xenotransplantation coincided with the JDRF moratorium on islet allotrans-
plantation in 2007. These incidences demonstrate that the risk of infectious diseases is
problematic not only in xenotransplantation but also in allotransplantation. Stringent
measures are necessary to regulate both experimental and routine transplantation (US
Food and Drug Administration (FDA) 2001; US Food and Drug Administration (FDA)
2003; US Food and Drug Administration (FDA) 2007). Prior to any transplant proced-
ure, a risk/benefit assessment is imperative regardless of the origins of graft organs or
tissue. In its 2009 report on xenotransplantation, the NHMRC did not discuss the JDRF
global moratorium on human islet transplantation. Yet, allotransplantation is also an
important point of comparison for its analysis of xenotransplantation. As noted above,
the NHMRC paper articulated the claim that ‘xenograft may be safer than allograft’
((National Health Medical Research Council (NHMRC) 2009b), 21). In its support of
clinical xenotransplantation, NHMRC advocated the practice of screening source pigs
and monitoring for infectious diseases without addressing the limitations of such pro-
cedures. Due to the possibility of human error, a rigorous and robust approach on the
regulation of clinical xenotransplantation would also need to take account of potential
accidents and inadvertence. British biochemist and Nobel laureate, Richard Roberts,
made the obvious point succinctly, ‘Humans are human. People make mistakes’ ((Sam-
ple I 2014), 32). With the expiry of the xenotransplantation moratorium in Canada,
Australia and elsewhere, it remains to be seen how clinical research in this field will un-
fold and whether developments in virology will have a bearing on the future trajectory
of experimental transplantation as has been the case in the past.
Abbreviation
FDA: US Food and Drug Administration.
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